Literature DB >> 20813973

No haploinsufficiency but loss of heterozygosity for EXT in multiple osteochondromas.

Christianne M A Reijnders1, Cathelijn J F Waaijer, Andrew Hamilton, Emilie P Buddingh, Sander P D Dijkstra, John Ham, Egbert Bakker, Karoly Szuhai, Marcel Karperien, Pancras C W Hogendoorn, Sally E Stringer, Judith V M G Bovée.   

Abstract

Multiple osteochondromas (MO) is an autosomal dominant disorder caused by germline mutations in EXT1 and/or EXT2. In contrast, solitary osteochondroma (SO) is nonhereditary. Products of the EXT gene are involved in heparan sulfate (HS) biosynthesis. In this study, we investigated whether osteochondromas arise via either loss of heterozygosity (2 hits) or haploinsufficiency. An in vitro three-dimensional chondrogenic pellet model was used to compare heterozygous bone marrow-derived mesenchymal stem cells (MSCs EXT(wt/-)) of MO patients with normal MSCs and the corresponding tumor specimens (presumed EXT(-/-)). We demonstrated a second hit in EXT in five of eight osteochondromas. HS chain length and structure, in vitro chondrogenesis, and EXT expression levels were identical in both EXT(wt/-) and normal MSCs. Immunohistochemistry for HS, HS proteoglycans, and HS-dependent signaling pathways (eg, TGF-β/BMP, Wnt, and PTHLH) also showed no differences. The cartilaginous cap of osteochondroma contained a mixture of HS-positive and HS-negative cells. Because a heterozygous EXT mutation does not affect chondrogenesis, EXT, HS, or downstream signaling pathways in MSCs, our results refute the haploinsufficiency theory. We found a second hit in 63% of analyzed osteochondromas, supporting the hypothesis that osteochondromas arise via loss of heterozygosity. The detection of the second hit may depend on the ratio of HS-positive (normal) versus HS-negative (mutated) cells in the cartilaginous cap of the osteochondroma.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20813973      PMCID: PMC2947289          DOI: 10.2353/ajpath.2010.100296

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  44 in total

1.  Diminished levels of the putative tumor suppressor proteins EXT1 and EXT2 in exostosis chondrocytes.

Authors:  M A Bernard; C E Hall; D A Hogue; W G Cole; A Scott; M B Snuggs; G A Clines; H J Lüdecke; M Lovett; W B Van Winkle; J T Hecht
Journal:  Cell Motil Cytoskeleton       Date:  2001-02

2.  Three Drosophila EXT genes shape morphogen gradients through synthesis of heparan sulfate proteoglycans.

Authors:  Yuki Takei; Yutakahiko Ozawa; Makoto Sato; Akira Watanabe; Tetsuya Tabata
Journal:  Development       Date:  2003-11-26       Impact factor: 6.868

3.  Not all perlecans are created equal: interactions with fibroblast growth factor (FGF) 2 and FGF receptors.

Authors:  Sarah Knox; Catherine Merry; Sally Stringer; James Melrose; John Whitelock
Journal:  J Biol Chem       Date:  2002-02-14       Impact factor: 5.157

4.  A method for the determination of the molecular weight and molecular-weight distribution of chondroitin sulphate.

Authors:  A Wasteson
Journal:  J Chromatogr       Date:  1971-07-08

5.  Two-color multiplex ligation-dependent probe amplification: detecting genomic rearrangements in hereditary multiple exostoses.

Authors:  Stefan J White; Geraldine R Vink; Marjolein Kriek; Wim Wuyts; Jan Schouten; Bert Bakker; Martijn H Breuning; Johan T den Dunnen
Journal:  Hum Mutat       Date:  2004-07       Impact factor: 4.878

6.  Hereditary multiple exostosis and chondrosarcoma: linkage to chromosome II and loss of heterozygosity for EXT-linked markers on chromosomes II and 8.

Authors:  J T Hecht; D Hogue; L C Strong; M F Hansen; S H Blanton; M Wagner
Journal:  Am J Hum Genet       Date:  1995-05       Impact factor: 11.025

7.  Distinct and collaborative roles of Drosophila EXT family proteins in morphogen signalling and gradient formation.

Authors:  Chun Han; Tatyana Y Belenkaya; Marat Khodoun; Miyuki Tauchi; Xinda Lin; Xinhua Lin
Journal:  Development       Date:  2004-03-03       Impact factor: 6.868

8.  Mutation and cancer: statistical study of retinoblastoma.

Authors:  A G Knudson
Journal:  Proc Natl Acad Sci U S A       Date:  1971-04       Impact factor: 11.205

9.  Embryonic fibroblasts with a gene trap mutation in Ext1 produce short heparan sulfate chains.

Authors:  Shuhei Yamada; Marta Busse; Momoyo Ueno; Olivia G Kelly; William C Skarnes; Kazuyuki Sugahara; Marion Kusche-Gullberg
Journal:  J Biol Chem       Date:  2004-05-25       Impact factor: 5.157

10.  Spatial and temporal changes in the expression of fibroglycan (syndecan-2) during mouse embryonic development.

Authors:  G David; X M Bai; B Van der Schueren; P Marynen; J J Cassiman; H Van den Berghe
Journal:  Development       Date:  1993-11       Impact factor: 6.868

View more
  30 in total

1.  Epiphyseal abnormalities, trabecular bone loss and articular chondrocyte hypertrophy develop in the long bones of postnatal Ext1-deficient mice.

Authors:  Federica Sgariglia; Maria Elena Candela; Julianne Huegel; Olena Jacenko; Eiki Koyama; Yu Yamaguchi; Maurizio Pacifici; Motomi Enomoto-Iwamoto
Journal:  Bone       Date:  2013-08-17       Impact factor: 4.398

2.  Cell cycle deregulation and mosaic loss of Ext1 drive peripheral chondrosarcomagenesis in the mouse and reveal an intrinsic cilia deficiency.

Authors:  Carlos E de Andrea; Ju-Fen Zhu; Huifeng Jin; Judith V M G Bovée; Kevin B Jones
Journal:  J Pathol       Date:  2015-03-03       Impact factor: 7.996

Review 3.  Genetic alterations in chondrosarcomas - keys to targeted therapies?

Authors:  Andre M Samuel; Jose Costa; Dieter M Lindskog
Journal:  Cell Oncol (Dordr)       Date:  2014-01-24       Impact factor: 6.730

Review 4.  Glycobiology and the growth plate: current concepts in multiple hereditary exostoses.

Authors:  Kevin B Jones
Journal:  J Pediatr Orthop       Date:  2011 Jul-Aug       Impact factor: 2.324

Review 5.  Hereditary Multiple Exostoses: a review of clinical appearance and metabolic pattern.

Authors:  Giovanni Beltrami; Gabriele Ristori; Guido Scoccianti; Angela Tamburini; Rodolfo Capanna
Journal:  Clin Cases Miner Bone Metab       Date:  2016-10-05

Review 6.  The pathogenic roles of heparan sulfate deficiency in hereditary multiple exostoses.

Authors:  Maurizio Pacifici
Journal:  Matrix Biol       Date:  2017-12-24       Impact factor: 11.583

Review 7.  Osteochondromas: An Updated Review of Epidemiology, Pathogenesis, Clinical Presentation, Radiological Features and Treatment Options.

Authors:  Kostas Tepelenis; Georgios Papathanakos; Aikaterini Kitsouli; Theodoros Troupis; Alexandra Barbouti; Konstantinos Vlachos; Panagiotis Kanavaros; Panagiotis Kitsoulis
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

8.  Cartilage tumour progression is characterized by an increased expression of heparan sulphate 6O-sulphation-modifying enzymes.

Authors:  Cathelijn J F Waaijer; Carlos E de Andrea; Andrew Hamilton; Jolieke G van Oosterwijk; Sally E Stringer; Judith V M G Bovée
Journal:  Virchows Arch       Date:  2012-08-18       Impact factor: 4.064

Review 9.  Cell biology of osteochondromas: bone morphogenic protein signalling and heparan sulphates.

Authors:  Araceli Cuellar; A Hari Reddi
Journal:  Int Orthop       Date:  2013-06-15       Impact factor: 3.075

10.  Assessing the general population frequency of rare coding variants in the EXT1 and EXT2 genes previously implicated in hereditary multiple exostoses.

Authors:  Diana L Cousminer; Alexandre Arkader; Benjamin F Voight; Maurizio Pacifici; Struan F A Grant
Journal:  Bone       Date:  2016-09-09       Impact factor: 4.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.